Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Ligase BioPartners is a venture capital firm founded in Utrecht, Netherlands, with a mission to partner with researchers in transforming early-stage scientific discoveries into viable clinical solutions. Established to bridge the gap between scientific innovation and marketable healthcare products, the firm emphasizes improving patient outcomes and accessibility. The organization operates with a science-first approach, ensuring that investments are grounded in rigorous scientific validation.
Currently, Ligase BioPartners manages a focused portfolio and collaborates closely with the Oncode Institute and other partner institutions. This collaboration enhances their ability to support founding teams through hands-on company building, leveraging scientific expertise and industry connections. The firm is dedicated to addressing unmet clinical needs in the biotech and healthcare sectors.
Ligase BioPartners invests primarily in the biotech and healthcare sectors, targeting companies at the pre-seed, seed, and Series A stages. Their investment strategy centers on three key areas: durable therapies, accessible therapies, and addressing unmet clinical needs. Durable therapies focus on scientific approaches that provide lasting benefits, while accessible therapies emphasize scalable manufacturing and equitable distribution.
The firm actively seeks out innovative companies that are developing solutions for profound clinical needs, particularly those targeting patient populations with limited therapeutic options. Ligase BioPartners' close relationship with the Oncode Institute allows them to provide substantial support to founding teams, facilitating the development of groundbreaking clinical solutions.
Ligase BioPartners has invested in several notable companies within the biotech sector:
These companies exemplify Ligase BioPartners' commitment to supporting innovative solutions that address critical healthcare challenges.
Cheryl Zimberlin, Ph.D - Managing Director. Cheryl has extensive experience in the biotech sector, focusing on translating scientific research into commercial opportunities. She holds a Ph.D. in a relevant scientific field and has previously worked with leading biotech firms.
Shobhit Dhawan, Ph.D - Managing Director. Shobhit brings a strong background in healthcare investments and has a proven track record of supporting early-stage biotech companies. He also holds a Ph.D. and has been involved in various successful funding rounds.
What are Ligase BioPartners' investment criteria?
Ligase BioPartners focuses on biotech and healthcare companies at the pre-seed, seed, and Series A stages. They look for innovative solutions that address unmet clinical needs, particularly in durable and accessible therapies.
How can founders pitch to Ligase BioPartners?
Founders can reach out through the contact information provided on their website. A well-prepared pitch deck should include details about the scientific basis of the product, market potential, and the founding team's expertise.
What makes Ligase BioPartners different from other investors?
The firm emphasizes a science-first approach, leveraging their connections with the Oncode Institute to provide hands-on support and guidance to portfolio companies. This unique relationship enhances their ability to facilitate the development of clinical solutions.
What is the geographic focus of Ligase BioPartners?
Ligase BioPartners primarily invests in companies based in Europe, particularly those that align with their focus on biotech and healthcare.
What kind of support do portfolio companies receive?
Ligase BioPartners provides hands-on support, including operational guidance, strategic advice, and access to their extensive network within the scientific and healthcare communities.
What is the typical check size for investments?
While specific check sizes are not disclosed, Ligase BioPartners invests at the pre-seed, seed, and Series A stages, indicating a range that aligns with early-stage funding requirements.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.